The fund seeks dividend income and options premium income, with the potential for capital appreciation by investing in mega-and large-size companies across any size in the United States.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

Next, the research team invests in dividend-paying, equity securities that are listed on U.S. exchanges and to write (sell) covered call options on those securities.

Then the manager constructs a portfolio of stocks from a list of companies favored by the research team and allocates capital based on its conviction level.

In addition, the fund utilizes a set of values-based screens to avoid investing in companies that are materially involved in the production, distribution, retail, supply or licensing of alcohol or related products, or tobacco or related products.

The fund also avoids companies materially involved in gambling, or that are directly participating in providing abortions and/or the production of drugs marketed with the primary intent to terminate pregnancy.

Also, the fund excludes companies in its portfolio that are directly engaged in scientific research using stem cells derived from human embryos, fetal tissue or human embryo cloning techniques, or are involved in the production, distribution or retail of adult entertainment, or involved in the production, distribution, retail, supply or licensing of psychoactive recreational cannabis or derivative products.

The fund seeks current income and capital appreciation by investing in companies across any size outside the United States.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

Next, the research team invests in U.S. and non-U.S. dividend-paying stocks.

The team focuses on companies that have demonstrated above-median yield and a positive trend in dividend payouts and favorable earnings growth.

Then the manager constructs a portfolio of stocks from a list of companies favored by the research team and allocates capital based on its conviction level.

In addition, the fund utilizes a set of values-based screens to avoid investing in companies that are materially involved in the production, distribution, retail, supply or licensing of alcohol or related products, or tobacco or related products.

The fund also avoids companies materially involved in gambling, or that are directly participating in providing abortions and/or the production of drugs marketed with the primary intent to terminate pregnancy.

Also, the fund excludes companies in its portfolio that are directly engaged in scientific research using stem cells derived from human embryos, fetal tissue or human embryo cloning techniques, or are involved in the production, distribution or retail of adult entertainment, or involved in the production, distribution, retail, supply or licensing of psychoactive recreational cannabis or derivative products.

The fund may also invest in other investment companies and real estate investment trusts.

Additionally, the fund seeks to diversify its investments across a number of different countries throughout the world, and, invests in at least five different countries (including the U.S.).

The fund may invest no more than 40% of its net assets in securities of companies in emerging market countries.

The fund seeks capital appreciation in the long term by investing in mega-and large-size companies outside the United States.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

The fund looks to enhance its performance over that of its primary benchmark index by changing the relative weighting in the fund’s portfolio of equity securities of developed market companies and of emerging market companies.

Also, the process utilizes quantitative analysis to assess a company’s valuation, growth, dividend yield, and industry.

Next, the research team employs a set of values-based screens to avoid investing in companies that are materially involved in the production, distribution, retail, supply or licensing of alcohol or related products and involved in the production, distribution, retail, supply or licensing of tobacco or related products.

The fund also avoids investing in companies involved in gambling, or directly participating in providing abortions and/or the production of drugs marketed with the primary intent to terminate pregnancy.

The fund also avoids investing in companies that are directly engaged in scientific research using stem cells derived from human embryos, or directly involved in the production, distribution or retail of adult entertainment.

Also, the fund excludes companies that are directly involved in the production, distribution, retail, supply or licensing of psychoactive recreational cannabis or derivative products.

Then the manager constructs a portfolio of stocks from a list of companies favored by the research team and allocates capital based on its conviction level.

The manager invests in securities of companies in both developed and emerging non-U.S. markets.

However, the fund may invest up to 5% of its net assets in certain collective investment vehicles or derivatives that may hold or derive value from securities issued by otherwise excluded companies.

The fund seeks capital appreciation in the long term by investing in large-size companies in the United States.

The investment process is designed to enhance the fund’s performance over its benchmark index and utilizes an optimization process to target value and growth-oriented companies.

The process uses quantitative analysis to assess a company’s valuation, growth, dividend yield, and industry.

Next, the research team screens securities in accordance with the fund’s cultural values policies, and those companies failing to meet the criteria are removed from investment consideration.

The team applies a set of values-based screens to avoid investing in companies that are materially involved in the production, distribution, retail, supply or licensing of alcohol or related products and involved in the production, distribution, retail, supply or licensing of tobacco or related products.

The fund also avoids investing in companies involved in gambling, or directly participating in providing abortions and/or the production of drugs marketed with the primary intent to terminate pregnancy, directly engaged in scientific research using stem cells derived from human embryos, fetal tissue or human embryo cloning techniques, or directly involved in the production, distribution or retail of adult entertainment; or directly involved in the production, distribution, retail, supply or licensing of psychoactive recreational cannabis or derivative products.

The fund’s assets are allocated in an attempt to match the characteristics of a blend of the benchmark and two indices that are subcomponents of the benchmark namely a large-cap growth index and a large-cap value index.

The resulting portfolio controls for risk and seeks outperformance against the benchmark through exposure to growth and value factors.

The fund has the flexibility to invest up to 5% of its net assets in securities of non-US issuers not included in the benchmark index.
 

The fund seeks capital appreciation in the long term by investing in small- and mid-size companies in the United States.

The investment process is designed to enhance the fund’s performance over its benchmark index and utilizes an optimization process to target value- and growth-oriented companies.

The research team is using quantitative analysis to assess a company’s valuation, growth, and dividend yield.

The fund avoids owning securities that choose to profit from businesses that may be at odds with their personal convictions.

The fund has the flexibility to invest up to 5% of its total assets in securities of non-US issuers not included in the benchmark index.